

Voting Members in Attendance: Nadia Khan (President & Chair), Glen Doucet (Vice-President), Trevor Hudson (Treasurer), Simon Bacon, Alan Bell, Peter Bolli, Norman Campbell, Dylan Burger, Tavis Campbell, Lyne Cloutier, Mike Cloutier, Ross Feldman, Robert Gros, Fady Hannah-Shmouni, Robert Herman, Janusz Kaczorowski, Laura Kuyper, Alexander Leung, Richard Lewanczuk, Patrice Lindsay, Alexander Logan, Donna McLean, Martin Myers, Raj Padwal, Pierre Paradis, Doreen Rabi, Ernesto Schiffrin, Guy Tremblay, Ross Tsuyuki.

Staff: Angelique Berg (Corporate Secretary CEO), Nancy Beshay, Crystal Ceres, Paul Landers, Jodi McNutt, Rebecca Sedore.

MINUTES OF MEETING

1.0 Welcome and Call to Order

With quorum confirmed, the Chair called the meeting to order at 8:00 pm.

2.0 Voting Instructions

Communications Manager Crystal Ceres outlined voting instructions with the digital platform.

3.0 Approval of the Minutes of the 2017 AGM

Upon motion duly made by ERNESTO SCHIFFRIN, seconded by DOREEN RABI, and unanimously carried, the minutes of the October 14, 2017 Annual General Meeting of Members were approved as circulated.

4.0 President's Report

The Chair recalled Hypertension Canada's Vision that Canadians will have the healthiest and best managed blood pressure in the world, and its core areas of excellence: knowledge translation, research, and advocacy. The Chair noted the strategic goals are (1) to expand influence and engagement among key target audiences including primary care, physicians, pharmacists, nurses and dietitians, and (2) to grow total revenues through optimizing traditional funding sources and diversifying total funding sources. Together, they focus efforts toward the Mission: to advance health through the prevention and control of hypertension and its complications.

The Chair reported on the organization's renewal of its core activities to best consider the current challenges faced by key stakeholders: the Hypertension Canada Guidelines transitioned to a two-year review cycle to enable a longer implementation cycle; improved research capacity is sought through trainee mentorship, including the 2019 Young Investigator Forum; and the Canadian Hypertension Congress' redesign aims to expand relevance and appeal to further strengthen research and advance knowledge translation. The Chair referred members to the 2018 Impact Report for more information.

The Chair announced the retirement, with thanks for their contributions, of four Directors, Barry Arbus, Ross Feldman, Sheldon Tobe, and Ross Tsuyuki. The Chair reported that these terms will remain vacant for a time, pending completion of a comprehensive Board Composition Plan to determine the ideal size, skills, diversity, and other factors to drive the organization's success.

The Chair concluded with invitation to the membership to be part of the innovation and momentum to lead the world in best managed blood pressure.

5.0 Operations Report

CEO Angelique Berg reported on Operations activity since the 2017 meeting across the organization's pillars of research, education and advocacy.

In research, Ms. Berg reported that the 2017 Canadian Hypertension Congress hosted 74 abstract presenters, and over 40 trainees at the inaugural Young Investigator Forum. Since, further action to develop trainee capacity includes their direct engagement in the next Young Investigator Forum planning committee, in development of a Research Trainee Strategy in partnership with CIHR's Institute of Circulatory and Respiratory Health, and in conference trainee exchanges.

In education, Ms. Berg reported greatly expanded reach of the Hypertension Canada Guidelines tools among primary care professionals. Current mid-year results in various indicators already near or exceed last year's total results, including the Hypertension Canada Guidelines highlights booklets circulation, the Guidelines digital app downloads, health care professionals education through in-person, online and partnered CME programs, and over 670,000 website visits in the first six months since its re-launch. Ms. Berg remarked that these increases are likely influenced in part by Hypertension Canada's presentations and booth presence at every national primary care conference in the last 12 months.

In advocacy, Ms. Berg reported that the re-launch of the Blood Pressure Measurement Device Recommendation Program in Hypertension Month, resulted in over 37 million media impressions and generated attention from around the world. Arising from this, Hypertension Canada is exploring collaboration with Health Canada on post-market surveillance of devices as part of efforts to improve accuracy in blood pressure detection and monitoring.

Ms. Berg noted that a small surplus was achieved in the 2018 financial results. She cautioned that this positive indication is but one year's results, and that priority remains growth in revenue to power the Mission, and expanded influence to improve hypertension control rates. She expressed gratitude to the membership for their engagement, and for their generosity of time and expertise.

There were no questions from the floor. The Chair thanked Ms. Berg for her presentation.

6.0 Presentation of Audited Financial Statements and Appointment of Auditor

Treasurer Trevor Hudson, with thanks to fellow Finance Committee members Barry Arbus, John Floras, and Pavel Hamet, presented the Audited Financial Statements for the Fiscal Year ended April 30, 2018. He reported the third audit with auditors Grant Thornton LLP was comprehensive, clean and with good cooperation from staff and the accountant.

Upon motion duly made by TREVOR HUDSON, seconded by ROSS FELDMAN and unanimously carried, the Audited Financial Statements for the Fiscal Year Ended April 30, 2018 were confirmed by the members.

Upon motion duly made by TREVOR HUDSON, seconded by ERNESTO SCHIFFRIN and unanimously carried, Grant Thornton LLP was appointed as the auditor for the fiscal year ending April 30, 2019.

The Chair thanked Mr. Hudson for his presentation, and the Finance Committee for their work.

7.0 Election of Directors

Ms. Berg, on behalf of Vice-President and Governance Committee Chair Glen Doucet, extended thanks to Committee members Dorothy Morris and Guy Tremblay for their work on this year's Election Slate. Ms. Berg called attention to the pre-circulated 2018 Election Slate, noted that seven of fourteen terms are expiring, with three Directors standing for re-election and four Directors retiring. Ms. Berg acknowledged the contributions of the retiring Directors:

Mr. Barry Arbus, appointed to the Board in 2011 and officially elected in 2012, played a pivotal role in guiding Hypertension Canada's first staff through the administration and risk management aspects of its establishing merger. Mr. Arbus served on the Finance Committee since his election, as the Committee's Vice-Chair since 2016, drove the Research and Trainee Funds definitions, and encouraged fund development diversification throughout his service.

Dr. Ross Feldman served as Hypertension Canada's first President and Board Chair, elected in 2010. Dr. Feldman was instrumental to the organization's establishment, and to the inaugural Canadian Hypertension Congress in 2011. Dr. Feldman serves on the Awards and Guidelines Committees, and as Vice-Chair on the Research Policy Committee. His contributions were recognized with the Distinguished Service Award in 2006 and the George Fodor Award in 2010.

Dr. Sheldon Tobe, first elected in 2012, is a founding member of the Canadian Hypertension Education Program, now the Hypertension Canada Guidelines, and played a key role on the Transition Committee that facilitated the organization's establishing merger. Dr. Tobe continues to serve on the Guidelines and Research Policy Committees, and his dedication to Hypertension Canada was recognized with a Certificate of Excellence in 2008.

Dr. Ross Tsuyuki was a founding Board member, elected in 2010, and played a key role on Hypertension Canada's Transition Committee, among many others. Dr. Tsuyuki continues to serve on the Guidelines Committee, as Co-Chair of the Research Policy and Education & Implementation Committees, and chairs the 2019 Canadian Hypertension Congress Scientific Program Committee. His dedication was honoured in 2007 with a Certificate of Excellence.

Ms. Berg called attention to the three Directors nominated for re-election: Alan Bell and Guy Tremblay to two year terms, and Ernesto Schiffrin to a one-year term only, at which point Dr. Schiffrin will reach the maximum allowable consecutive years of service.

Dr. Alan Bell is a family physician, clinical researcher, and an Assistant Professor of Family and Community Medicine at the University of Toronto. Dr. Bell serves on various guideline committees of the Canadian Cardiovascular Society, and as Vice-Chair of Thrombosis Canada. He has served as faculty and chair of various committees and advisory boards in continuing medical education, serving the common interests of the medical profession and the public. First elected in 2016, Dr. Bell co-chairs the Education & Implementation Committee, and will co-chair the 2019 Canadian Hypertension Congress.

Dr. Ernesto Schiffrin is Physician-in-Chief at Montreal's Jewish General Hospital, a world- renowned scientist, recipient of numerous awards within Canada and internationally, and was invested to the Order of Canada for his research in the field of hypertension. First elected in 2011, Dr. Schiffrin serves on the Executive, Research Policy, and Guidelines Committees, and is immediate Past-President.

Dr. Guy Tremblay is a cardiologist, epidemiologist and health services researcher, and professor of internal medicine in Quebec City. He has played a leading role in the widespread dissemination and adoption of clinical practice guidelines, including those of the Canadian Cardiovascular Society and Hypertension Canada.

Upon motion duly made by ROSS FELDMAN, seconded by TREVOR HUDSON and unanimously carried, each of the following were elected as a Director of the Board: Dr. Alan Bell and Dr. Guy Tremblay to two-year terms, and Dr. Ernesto Schiffrin to a one-year term.

Ms. Berg thanked the membership for their votes and announced that those elected join Directors with terms-in-progress: Glen Doucet, Trevor Hudson, Janusz Kaczorowski, Nadia Khan, David Lui, Dorothy Morris, and Raj Padwal; to form the 2018-2019 Board of Directors.

The Chair thanked Ms. Berg for facilitating the election, and the Governance Committee for their work on the 2018 Election Slate and on the Board Composition Plan.

8.0 Remarks and Close

The Chair thanked everyone for their participation in this 2018 Annual General Meeting and in the organization throughout the year.

The Chair encouraged attendance at the 2019 Canadian Hypertension Congress, September 25-28, 2019, and wide promotion of the event by all members.

There being no further business, the meeting was closed at 8:51 pm.

Respectfully submitted to the Board of Directors,



Jodi McNutt for:
Angelique Berg,
Corporate Secretary
November 29, 2018